PURPOSE: The 388A>G and the 521T>C polymorphism of the SLCO1B1 gene affect the activity of the uptake transporter OATP1B1, thus influencing kinetics, safety, and efficacy of substrate drugs. To evaluate the impact of these polymorphisms in populations of different ethnic origins, it is important to know their frequencies and to develop fast and reliable methods for genotyping. We therefore established a new, high-throughput method and determined the genotype and allelic frequencies of these polymorphisms in Tanzanians, for which the frequencies were unknown thus far. METHODS: New LightCycler® 480-based methods with hybridization probes were established and used to genotype 366 Tanzanian and 236 European individuals for 388A>G (rs2306283) and 521T>C (rs4149056) in the SLCO1B1 gene. The methods were validated by direct sequencing of the polymerase chain reaction (PCR) products of heterozygous individuals and checked for intrarun precision repeatability, interrun precision reproducibility, robustness, and deviations from the Hardy-Weinberg equilibrium. RESULTS: The new methods allow unambiguous identification of the corresponding genotypes. There was a clear difference in allelic distribution between Tanzanians and Europeans, with the 388A>G (rs2306283) being much more prevalent in Tanzanians (87% vs 41%) and the 521T>C (rs4149056) being very rare in this African population (6% vs 17%). CONCLUSIONS: We developed robust and high-throughput methods to genotype common SLCO1B1 allelic variants with the LightCycler® 480. In Tanzanians, we identified the highest frequency of the 388A>G and 521T>C polymorphisms ever reported from black populations. The clinical relevance of SLCO1B1 genetic variation in the African population remains to be investigated.
PURPOSE: The 388A>G and the 521T>C polymorphism of the SLCO1B1 gene affect the activity of the uptake transporter OATP1B1, thus influencing kinetics, safety, and efficacy of substrate drugs. To evaluate the impact of these polymorphisms in populations of different ethnic origins, it is important to know their frequencies and to develop fast and reliable methods for genotyping. We therefore established a new, high-throughput method and determined the genotype and allelic frequencies of these polymorphisms in Tanzanians, for which the frequencies were unknown thus far. METHODS: New LightCycler® 480-based methods with hybridization probes were established and used to genotype 366 Tanzanian and 236 European individuals for 388A>G (rs2306283) and 521T>C (rs4149056) in the SLCO1B1 gene. The methods were validated by direct sequencing of the polymerase chain reaction (PCR) products of heterozygous individuals and checked for intrarun precision repeatability, interrun precision reproducibility, robustness, and deviations from the Hardy-Weinberg equilibrium. RESULTS: The new methods allow unambiguous identification of the corresponding genotypes. There was a clear difference in allelic distribution between Tanzanians and Europeans, with the 388A>G (rs2306283) being much more prevalent in Tanzanians (87% vs 41%) and the 521T>C (rs4149056) being very rare in this African population (6% vs 17%). CONCLUSIONS: We developed robust and high-throughput methods to genotype common SLCO1B1 allelic variants with the LightCycler® 480. In Tanzanians, we identified the highest frequency of the 388A>G and 521T>C polymorphisms ever reported from black populations. The clinical relevance of SLCO1B1 genetic variation in the African population remains to be investigated.
Authors: E Ngaimisi; S Mugusi; O M Minzi; P Sasi; K-D Riedel; A Suda; N Ueda; M Janabi; F Mugusi; W E Haefeli; J Burhenne; E Aklillu Journal: Clin Pharmacol Ther Date: 2010-09-29 Impact factor: 6.875
Authors: Robert A M Op den Buijsch; Petal A H M Wijnen; Marja P van Dieijen-Visser; Johan E de Vries; Otto Bekers Journal: Pharmacogenomics Date: 2005-06 Impact factor: 2.533
Authors: I Ieiri; S Suwannakul; K Maeda; H Uchimaru; K Hashimoto; M Kimura; H Fujino; M Hirano; H Kusuhara; S Irie; S Higuchi; Y Sugiyama Journal: Clin Pharmacol Ther Date: 2007-04-25 Impact factor: 6.875
Authors: Stefan Oswald; Jörg König; Dieter Lütjohann; Thomas Giessmann; Heyo K Kroemer; Christian Rimmbach; Dieter Rosskopf; Martin F Fromm; Werner Siegmund Journal: Pharmacogenet Genomics Date: 2008-07 Impact factor: 2.089
Authors: Jorge A Pinto; Edmund V Capparelli; Meredith Warshaw; Bonnie Zimmer; Tim R Cressey; Stephen A Spector; Min Qin; Betsy Smith; George K Siberry; Mark Mirochnick Journal: Pediatr Infect Dis J Date: 2018-02 Impact factor: 2.129
Authors: Paulo Caleb Junior Lima Santos; Ana Carolina Moron Gagliardi; Márcio Hiroshi Miname; Ana Paula Chacra; Raul Dias Santos; Jose Eduardo Krieger; Alexandre Costa Pereira Journal: Eur J Clin Pharmacol Date: 2011-09-18 Impact factor: 2.953
Authors: Christoph Markert; Regina Hellwig; Jürgen Burhenne; Michael Marcus Hoffmann; Johanna Weiss; Gerd Mikus; Walter E Haefeli Journal: Eur J Clin Pharmacol Date: 2013-06-09 Impact factor: 2.953
Authors: Amy Webb; Audrey C Papp; Jonathan C Sanford; Kun Huang; Jeffrey D Parvin; Wolfgang Sadee Journal: Pharmacogenet Genomics Date: 2013-05 Impact factor: 2.089
Authors: Paulo C J L Santos; Renata A G Soares; Raimundo M Nascimento; George L L Machado-Coelho; José G Mill; José E Krieger; Alexandre C Pereira Journal: BMC Med Genet Date: 2011-10-12 Impact factor: 2.103